Antibody-directed enzyme prodrug therapy (ADEPT). (Q40912787)

24 September 2017

1 reference

title

Antibody-directed enzyme prodrug therapy (ADEPT). (English)

1 reference

24 September 2017

Bagshawe KD

1

1 reference

24 September 2017

publication date

1 January 1993

1 reference

24 September 2017

published in

Advances in Pharmacology

1 reference

24 September 2017

volume

24

1 reference

24 September 2017

page(s)

99-121

1 reference

Enhancement of the anti-tumor effect of melphalan in experimental mice by some vaso-active agents

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers—Where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Antibody directed enzymes revive anti-cancer prodrugs concept

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

A cytotoxic agent can be generated selectively at cancer sites

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Monoclonal antibodies in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Radioimmunolocalization of Tumours by External Scintigraphy after Administration of131I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Effects of sodium butyrate on synthesis of human chorionic gonadotrophin in trophoblastic and non-trophoblastic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

In vivo tumor targeting of a recombinant single-chain antigen-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Specific immunosuppression by immunotoxins containing daunomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Mapping epitope characteristics on carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Carboxypeptidase-mediated release of methotrexate from methotrexate alpha-peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Trimetrexate: a second generation folate antagonist in clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

The kinetics of antibody binding to membrane antigens in solution and at the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Recombinant antibodies possessing novel effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

A human choriocarcinoma xenograft in nude mice, a model for the study of antibody localization

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

The potential of carboxypeptidase G2-antibody conjugates as anti-tumour agents. I. Preparation of antihuman chorionic gonadotrophin-carboxypeptidase G2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

A new strategy for the generation of catalytic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Development of alkylating agent-resistant human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

Stimulation of human chorionic gonadotropin secretion by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960935-7

7 January 2021

10.1016/S1054-3589(08)60935-7

Identifiers

DOI

0 references

1 reference